N‐glycosylation of PD‐1 promotes binding of camrelizumab

PD‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD‐1 with monoclonal antibodies (MAbs) to block the interaction with its ligand PD‐L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N‐glycosylation sites of PD‐1 exist in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:EMBO Rep
Main Authors: Liu, Kefang, Tan, Shuguang, Jin, Wanjun, Guan, Jiawei, Wang, Qingling, Sun, Huan, Qi, Jianxun, Yan, Jinghua, Chai, Yan, Wang, Zhongfu, Deng, Chuxia, Gao, George F
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7726772/
https://ncbi.nlm.nih.gov/pubmed/33063473
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.202051444
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados